Simplify Logo

Full-Time

Group Leader

Metabolism

Posted on 11/9/2023

NewLimit

NewLimit

11-50 employees

Medicines for healthspan extension via epigenetics

Biotechnology
Healthcare

Senior, Expert

San Bruno, CA, USA

Category
Biology Lab & Research
Biology & Biotech
Requirements
  • Ph.D. in cell biology, molecular biology, biochemistry or a related field or equivalent industry experience (5+ years)
  • Experience leading a cross-functional team and managing direct reports
  • Experience with therapeutic development, as demonstrated through contributions to a pre-clinical or clinical stage program
  • Experience designing and executing experiments in animal models
  • Experience with target ID and validation
Responsibilities
  • Lead a team of Scientists (liver biologists) and Research Associates to develop epigenetic reprogramming therapies while remaining involved in day-to-day execution
  • Collaborate with our Single Cell Technology, Epigenetic Editing, and Predictive Modeling teams to design, build, and test epigenetic reprogramming interventions for aged and diseased hepatocytes
  • Contribute to NewLimit’s product development decisions, company-wide goals, and technology platform
  • Serve as a company-wide expert on metabolic diseases and liver biology
  • Develop assays to measure hepatocyte function both ex vivo and in vivo
  • Evaluate epigenetic reprogramming payloads using ex vivo and in vivo functional assays to select therapeutic candidates

NewLimit develops medicines aimed at extending human healthspan by reprogramming aging cells' epigenomes. This process involves changing the chemical modifications on DNA and histone proteins to restore youthful functions in old cells, focusing initially on rejuvenating the immune system and liver. The company uses advanced technologies like single-cell genomics and machine learning to identify aging markers and create interventions that reverse these changes. NewLimit targets the healthcare market, serving pharmaceutical companies, healthcare providers, and individuals seeking anti-aging treatments. Its goal is to create a new class of medicines that significantly increase the period of life spent in good health.

Company Stage

Series A

Total Funding

$40M

Headquarters

South San Francisco, California

Founded

2022

Growth & Insights
Headcount

6 month growth

18%

1 year growth

45%

2 year growth

88%
Simplify Jobs

Simplify's Take

What believers are saying

  • Securing $40 million in Series A funding from prominent investors provides a strong financial foundation for growth and innovation.
  • NewLimit's pioneering approach to reversing aging could lead to groundbreaking treatments for age-related diseases, offering significant societal impact.
  • Partnerships with pharmaceutical companies and healthcare providers could accelerate the commercialization and adoption of their anti-aging medicines.

What critics are saying

  • The field of epigenetic reprogramming is still in its infancy, posing scientific and regulatory challenges that could delay product development.
  • High reliance on advanced technologies like machine learning and single-cell genomics may lead to operational complexities and increased costs.

What makes NewLimit unique

  • NewLimit focuses on epigenetic reprogramming to extend healthspan, a niche yet revolutionary approach in the biotech industry.
  • The integration of single-cell genomics, machine learning, and high-throughput functional assays sets NewLimit apart from traditional biotech firms.
  • Co-founded by high-profile individuals like Coinbase CEO Brian Armstrong, NewLimit benefits from strong financial backing and industry connections.

Help us improve and share your feedback! Did you find this helpful?

INACTIVE